EXEL Exelixis
- 21.630
- -0.130-0.60%
Exelixis News
Form 144 | Exelixis(EXEL.US) Director Proposes to Sell 264.1K in Common Stocks
SEC FILLINGS DISCLOSED/ May 7, $Exelixis(EXEL.US)$ Director POSTE GEORGE intends to sell 11,686 shares of its common stock on May 7, with a total market value of approximately $264.1K. Source: Anno
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif.--(BUSINESS WIRE)--May 7, 2024-- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will par
Exelixis (EXEL) International Revenue Performance Explored
HC Wainwright & Co. : The Exelixis (EXEL.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $28.00.
HC Wainwright & Co. : The Exelixis (EXEL.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $28.00.
HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $28 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $28 price target.
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript
Exelixis, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Exelixis, Inc. (NASDAQ:EXEL) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters. Results showed a clear earnings miss, with US$425m revenue coming in 7
Hold Rating on Exelixis: Analyzing Q1 Revenue Shortfalls and Pipeline Progress
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
Exelixis (NASDAQ:EXEL) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below offers a condensed view of their recent ratings,
Exelixis Is Maintained at Buy by TD Cowen
Exelixis Is Maintained at Buy by TD Cowen
TD Cowen Maintains Buy on Exelixis, Raises Price Target to $27
TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $25 to $27.
Exelixis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 24.14% TD Cowen $25 → $27 Maintains Buy 04/11/2024 14.94% Barclays $25 → $25 Downgrades Overwei
Exelixis Down Over 9%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
Exelixis, Inc. ( EXEL ) is currently at $21.20, down $2.26 or 9.61% --Would be lowest close since Feb. 22, 2024, when it closed at $20.71 --On pace for largest percent decrease since May 19, 2022, w
RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept
Exelixis (EXEL) has an average rating of outperform and price targets ranging from $18 to $32.35, according to analysts polled by Capital IQ. Price: 21.40, Change: -2.07, Percent Change: -8.80
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
Exelixis (EXEL) Receives a Buy From Bank of America Securities
Earnings Call: Exelixis Maintains 2024 Guidance on Strong Q1 Results
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Zynex (ZYXI)
Analysts Are Bullish on These Healthcare Stocks: Exelixis (EXEL), Cyclo Therapeutics (CYTH)
Analysis
Price Target
No Data
